TISSUE SEALING MEDICINAL AGENTS GROUP ON THE PHARMACEUTICAL MARKET OF THE REPUBLIC OF BELARUS

Vestnik of Vitebsk State Medical University Pub Date : 2021-08-17 DOI:10.22263/2312-4156.2021.4.67

V. Novitskaya, S. E. Rzheussky

{"title":"TISSUE SEALING MEDICINAL AGENTS GROUP ON THE PHARMACEUTICAL MARKET OF THE REPUBLIC OF BELARUS","authors":"V. Novitskaya, S. E. Rzheussky","doi":"10.22263/2312-4156.2021.4.67","DOIUrl":null,"url":null,"abstract":"The purpose of this article was to analyze the pharmaceutical market of the tissue sealing agents group of the Republic of Belarus from 2010 to 2018 based on the data presented in the Medmarket database and the State Register of Medicines of the Republic of Belarus of UE «Center of Expertise and Testing in Healthcare». The group of tissue sealing agents (B02F) was found to be characterized by high growth rates and a relatively large market share. During the studied period, it was represented on the Belarusian pharmaceutical market by only one drug - Tachocomb (manufactured by Takeda Pharmaceutical Company Limited, Japan). When analyzing its dynamics in the period from 2010 to 2018 it was found that, in general, the change in the volume of the market for tissue sealing agents correlates with the change in the volume of the total market for hemostatic drugs over the years. During 2010-2018 there is an increase in the volume of sales for this local sealant, both in monetary (by 1.51) and in natural (by 2.01) expressions with a gradual fall of the price. It has been concluded that the development of the tissue sealing agents by domestic manufacturers is urgent and expedient.","PeriodicalId":23571,"journal":{"name":"Vestnik of Vitebsk State Medical University","volume":"64 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vestnik of Vitebsk State Medical University","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22263/2312-4156.2021.4.67","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The purpose of this article was to analyze the pharmaceutical market of the tissue sealing agents group of the Republic of Belarus from 2010 to 2018 based on the data presented in the Medmarket database and the State Register of Medicines of the Republic of Belarus of UE «Center of Expertise and Testing in Healthcare». The group of tissue sealing agents (B02F) was found to be characterized by high growth rates and a relatively large market share. During the studied period, it was represented on the Belarusian pharmaceutical market by only one drug - Tachocomb (manufactured by Takeda Pharmaceutical Company Limited, Japan). When analyzing its dynamics in the period from 2010 to 2018 it was found that, in general, the change in the volume of the market for tissue sealing agents correlates with the change in the volume of the total market for hemostatic drugs over the years. During 2010-2018 there is an increase in the volume of sales for this local sealant, both in monetary (by 1.51) and in natural (by 2.01) expressions with a gradual fall of the price. It has been concluded that the development of the tissue sealing agents by domestic manufacturers is urgent and expedient.

查看原文本刊更多论文

组织密封医药制剂集团在白俄罗斯共和国医药市场

本文的目的是分析2010年至2018年白俄罗斯共和国组织密封剂组的药品市场，数据基于Medmarket数据库和白俄罗斯共和国国家药品注册中心的UE«医疗保健专业知识和测试中心»。组织密封剂(B02F)组的特点是高增长率和相对较大的市场份额。在研究期间，白俄罗斯医药市场上只有一种药物——Tachocomb(由日本武田制药有限公司生产)。通过对2010 - 2018年的动态分析发现，总体而言，组织密封剂市场规模的变化与各年止血药物总市场规模的变化相关。在2010-2018年期间，随着价格的逐渐下降，这种当地密封胶的销量有所增加，以货币形式(1.51)和自然形式(2.01)表示。研究表明，国内生产企业开发组织密封剂是当务之急。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vestnik of Vitebsk State Medical University

自引率

0.00%

发文量